Zobrazeno 1 - 10
of 90
pro vyhledávání: '"Alan K Burnett"'
Autor:
Alan K Burnett, Emma Das Gupta, Steve Knapper, Asim Khwaja, Marion Sweeney, Lars Kjeldsen, Timothy Hawkins, Sophie E Betteridge, Paul Cahalin, Richard E Clark, Robert K Hills, Nigel H Russell
Publikováno v:
Haematologica, Vol 103, Iss 10 (2018)
As part of the UK NCRI AML17 trial, adult patients with acute myeloid leukemia in remission could be randomized to receive the mammalian target of rapamycin inhibitor everolimus, sequentially with post-induction chemotherapy. Three hundred and thirty
Externí odkaz:
https://doaj.org/article/137ea70794c64954ac9332b82770f208
Autor:
Naeem Khan, Robert K Hills, Steve Knapper, Lora Steadman, Ushna Qureshi, Jerrald L Rector, Charlotte Bradbury, Nigel H Russell, Paresh Vyas, Alan K Burnett, David Grimwade, Paul S Hole, Sylvie D Freeman
Publikováno v:
PLoS ONE, Vol 11, Iss 9, p e0163291 (2016)
In acute myeloid leukemia (AML) quiescence and low oxidative state, linked to BCL2 mitochondrial regulation, endow leukemic stem cells (LSC) with treatment-resistance. LSC in CD34+ and more mature CD34- AML have heterogeneous immunophenotypes overlap
Externí odkaz:
https://doaj.org/article/08d6f25f419e49eab87480ffd98ec9d5
Autor:
Alan K Burnett
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 5, Iss 1, Pp e2013038-e2013038 (2013)
There has been a gradual improvement in the outcome for younger patients with Acute Myeloid Leukaemia over the last two decades, but unfortunately this same progress is not apparent in older patients. “Old” has come to mean rather arbitrarily, pa
Externí odkaz:
https://doaj.org/article/61f7971328d8456a9b58a378dd0ca06b
Autor:
Yanis Tazi, Juan E. Arango-Ossa, Yangyu Zhou, Elsa Bernard, Ian Thomas, Amanda Gilkes, Sylvie Freeman, Yoann Pradat, Sean J. Johnson, Robert Hills, Richard Dillon, Max F. Levine, Daniel Leongamornlert, Adam Butler, Arnold Ganser, Lars Bullinger, Konstanze Döhner, Oliver Ottmann, Richard Adams, Hartmut Döhner, Peter J. Campbell, Alan K. Burnett, Michael Dennis, Nigel H. Russell, Sean M. Devlin, Brian J. P. Huntly, Elli Papaemmanuil
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-16 (2022)
Classification and risk-stratification for Acute Myeloid Leukemia (AML) at diagnosis are primarily based on cytogenetics and only a few gene mutations. Here, the authors study the genomic landscape of 3653 AML patients and characterize 16 non-overlap
Externí odkaz:
https://doaj.org/article/f0c1b3c2c89c4431b1bfec535238074b
Autor:
Francis Mussai, Carmela De Santo, Paul Cheng, Ian F. Thomas, Cono Ariti, Laura Upton, Ugo Scarpa, Victoria Stavrou, Mia Sydenham, Alan K. Burnett, Steven K. Knapper, Priyanka Mehta, Mary F. McMullin, Mhairi Copland, Nigel H. Russell, Mike Dennis
Publikováno v:
British Journal of Haematology. 200:573-578
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4d46208595d103723549ab46f86de175
https://doi.org/10.1111/bjh.18560
https://doi.org/10.1111/bjh.18560
Publikováno v:
British Journal of Haematology. 196:1348-1352
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::94ab7a979d369a9975762fbf5b1327ce
https://doi.org/10.1111/bjh.17981
https://doi.org/10.1111/bjh.17981
Autor:
Mhairi Copland, Ian Thomas, Nigel H. Russell, Richard E. Clark, Robert Kerrin Hills, Cono Ariti, Priyanka Mehta, Michael Dennis, Steven Knapper, Laura Upton, Rohini Radia, Amanda F. Gilkes, Claire Hemmaway, Alan K. Burnett
Publikováno v:
Blood Advances
Key Points First report of an FLT3-targeted therapy added to nonintensive chemotherapy that has improved survival in older FLT3-ITD patients with AML.Quizartinib is well tolerated, improves response and survival in older FLT3-ITD AML patients and mer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::947c8117ccc63e5664af5a159d9fb5a5
http://europepmc.org/articles/PMC8714727
http://europepmc.org/articles/PMC8714727
Autor:
Francis, Mussai, Carmela, De Santo, Paul, Cheng, Ian F, Thomas, Cono, Ariti, Laura, Upton, Ugo, Scarpa, Victoria, Stavrou, Mia, Sydenham, Alan K, Burnett, Steven K, Knapper, Priyanka, Mehta, Mary F, McMullin, Mhairi, Copland, Nigel H, Russell, Mike, Dennis
Publikováno v:
British journal of haematologyREFERENCES.
The survival of acute myeloid leukaemia (AML) patients aged over 60 has been suboptimal historically, whether they are treated using hypomethylating agents, low-dose cytarabine (LDAC) or venetoclax-based regimens. Progress is being made, however, for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7ea80bffb99fd227fedf0697f296a221
https://pubmed.ncbi.nlm.nih.gov/36413792
https://pubmed.ncbi.nlm.nih.gov/36413792
Autor:
Megan Othus, Ian Thomas, Xu Wang, Cono Ariti, Priyanka Mehta, Mia Sydenham, Robert K. Hills, Alan K. Burnett, Sucha Nand, Sarit Assouline, Laura C. Michaelis, Harry P. Erba, Nigel Russell, Kathleen F. Kerr, Roland B. Walter, Mike Dennis
Publikováno v:
Leukemialymphoma.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d06e433bd24fae7311a7f201069ab11
https://pubmed.ncbi.nlm.nih.gov/36226777
https://pubmed.ncbi.nlm.nih.gov/36226777
Autor:
Nigel H. Russell, Robert K. Hills, Lars Kjeldsen, Richard E. Clark, Sahra Ali, Paul Cahalin, Ian F. Thomas, Alan K. Burnett
The prognosis for younger patients with relapsed acute myeloid leukaemia (AML) is generally dismal. Allogeneic stem cell transplantation is the preferred therapy for these patients. As part of the UK NCRI AML17 trial, daunorubicin/clofarabine (DClo)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1f716c1ce573d298177610e141eff84
